三分之一常规剂量光敏剂维替泊芬联合光动力疗法治疗急性中心性浆液性脉络膜视网膜病变多中心临床效果观察  

The Clinical Effect of Photodynamic Therapy with 1/3 Conventional-dose Verteporfin on Acute Central Serous Chorioretinopathy

作　　者：党维华[1] 于沛涛[2] 刘宁宁[3] 王冠晶 吕玲[1] 

机构地区：[1]沈阳医学院沈洲医院眼科,辽宁省沈阳市110002 [2]北京大学医学部基础医学院 [3]中国医科大学第一临床学院眼科 [4]沈阳市第四人民医院眼科

出　　处：《中国全科医学》2014年第21期2510-2512,共3页Chinese General Practice

摘　　要：目的观察1/3常规剂量光敏剂维替泊芬联合光动力疗法(PDT)治疗急性中心性浆液性脉络膜视网膜病变(CSC)的有效性和安全性。方法选取2011年10月—2012年10月沈阳医学院沈洲医院、中国医科大学第一临床学院、沈阳市第四人民医院确诊的急性CSC患者90例(90眼),均接受1/3常规剂量维替泊芬静脉推注(2 mg/m2),静脉推注开始5 min后接受波长689 nm激光照射83 s。治疗后1周和1、3、6个月随访,比较治疗前后最佳矫正视力(BCVA)、视网膜下积液面积、黄斑中心凹视网膜厚度(CFT),观察不良反应。结果治疗后较治疗前BCVA提高,视网膜下积液面积减少,CFT变薄(P<0.05)。BCVA、视网膜下积液面积、CFT治疗前到治疗后1个月内明显好转,治疗后1个月到6个月基本稳定,无不良反应发生。结论 1/3常规剂量光敏剂维替泊芬联合PDT治疗急性CSC能停止或减少脉络膜血管渗漏,促进视网膜解剖复位,改善症状,提高和稳定视力,无明显不良反应。ObjectiveToobservethetherapeuticeffectandsafetyofphotodynamictherapy（PDT）with1/3conven-tional-doseverteporfinonacutecentralserouschorioretinopathy（CSC）.Methods 90patients（90eyes）whowerediagnosed as acute CSC in Shenzhou Hospital Affiliated to Shenyang Medical College , the First Affiliated Hospital of China Medical Univer-sity, and Shenyang Fourth People′s Hospital from October 2011 to October 2012, were selected as study subjects .All patients ac-cepted intravenous injection of 1/3 conventional-dose verteporfin （2 mg/m2 ）, 5 min later, patients received laser irradiation （689 nm） for 83 s.The follow -up time point was 1 week, 1, 3, 6 months after treatment.The best corrected visual acuity （BCVA）, area of subretinal fluid and central fovea thichness （CFT） were compared before and after treatment , and the adverse reactions were recorded .Results The BCVA after treatment was significantly higher than that before treatment , area of subretinal fluid after treatment was significantly smaller than that before treatment , CFT after treatment was significantly thinner than that be-fore treatment （all P〈0.05） .The BCVA, area of subretinal fluid and CFT 1 month after treatment were much better those be-fore treatment, the BCVA and area of subretinal fluid and CFT kept stability from 1 month after treatment to 6 months after treat-ment, no adverse reaction occurred within this period .Conclusion PDT with 1/3 conventional-dose verteporfin for acute CSC could improve symptoms , improve and maintain visual acuity , prevent or reduce the leakage from choroidal vascular , promote anatomical reposition of retinal , and have no obvious adverse reactions .

关 键 词：视网膜疾病 光敏感药 维替泊芬 光化学疗法 

分 类 号：R774.1[医药卫生—眼科]